United States Biotechnology & Medical Research

FibroGen Inc (FGEN)

Track

FibroGen Inc. has seen recent insider activity characterized by multiple buy transactions from CEO Thane Wettig. The most recent trading occurred on November 17, 2025, when the CEO acquired 2,700 shares. These purchases follow a series of buy transactions executed by company leadership throughout 2025, reflecting consistent acquisition activity by executives.
Ticker: FGEN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for FibroGen Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 17 Nov 2025
Value US$2,490,824.02 | Price 419.07 | Shares 90,964 (-44.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-17 2025-11-17 B Purchase
3.6
Wettig Thane

CEO

Executive Director
90,964 -44.1%
419.07
US$2,490,824 		90,964 -44.1% 419.07 US$2,490,824
2025-11-17 2025-11-13 B Purchase
3.6
Wettig Thane

CEO

Executive Director
75,147 -37.7%
338.48
US$4,830,116 		75,147 -37.7% 338.48 US$4,830,116
2025-07-02 2025-06-30 B Purchase
3.1
Schoeneck James A
Non-Executive Director
9,356 -8.1%
349.78
US$1,829,287 		9,356 -8.1% 349.78 US$1,829,287
2025-03-25 2025-03-24 B Purchase
3.6
Wettig Thane

CEO

Executive Director
145,000 +36.4%
0.35
US$50,663 		145,000 +36.4% 0.35 US$50,663
2025-03-24 2025-03-21 B Purchase
3.1
Schoeneck James A
Non-Executive Director
50,000 +15.4%
0.34
US$17,040 		50,000 +15.4% 0.34 US$17,040
2025-03-24 2025-03-20 B Purchase
3.1
Schoeneck James A
Non-Executive Director
250,000 +339.1%
0.35
US$88,000 		250,000 +339.1% 0.35 US$88,000
2024-06-13 2024-06-12 B Purchase
0.5
Adib Deyaa

Chief Medical Officer

Officer
22,123 +36.9%
1.17
US$25,884 		22,123 +36.9% 1.17 US$25,884
2024-03-11 2024-03-07 B Purchase
3.6
Wettig Thane

CEO

Officer
50,000 +11.9%
1.91
US$95,470 		50,000 +11.9% 1.91 US$95,470
2023-09-06 2023-09-01 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -6.5%
1.03
US$2,060 		2,000 -6.5% 1.03 US$2,060
2023-09-01 2023-09-01 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
1.06
US$2,120 		2,000 1.06 US$2,120
2023-08-08 2023-08-04 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -6.1%
1.91
US$3,820 		2,000 -6.1% 1.91 US$3,820
2023-08-04 2023-08-04 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
1.91
US$3,820 		2,000 1.91 US$3,820
2023-07-13 2023-07-11 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,000 -5.7%
2.69
US$5,380 		2,000 -5.7% 2.69 US$5,380
2023-07-11 2023-07-11 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
2,000
2.73
US$5,460 		2,000 2.73 US$5,460
2023-07-10 2023-07-07 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
1,880 -0.5%
2.80
US$5,264 		1,880 -0.5% 2.80 US$5,264
2023-06-26 2023-06-23 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
791 -0.7%
16.53
US$13,075 		791 -0.7% 16.53 US$13,075
2023-06-23 2023-06-23 PrS Proposed sale
3.6
Wettig Thane

Officer

Officer
791
16.53
US$13,075 		791 16.53 US$13,075
2023-06-15 2023-06-14 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
1,000 -0.4%
17.46
US$17,460 		1,000 -0.4% 17.46 US$17,460
2023-06-15 2023-06-14 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
5,250 -2.2%
16.66
US$87,465 		5,250 -2.2% 16.66 US$87,465
2023-06-15 2023-06-13 PlS Planned sale
3.9
Chung Christine

SVP, China Operations

Officer
6,250 -2.5%
17.60
US$110,000 		6,250 -2.5% 17.60 US$110,000
2023-06-13 2023-06-13 PrS Proposed sale
3.9
Christine Chung

Officer

Officer
62,500
17.56
US$1,097,500 		62,500 17.56 US$1,097,500
2023-06-09 2023-06-09 PrS Proposed sale
AOIFE BRENNAN

Director

Non-Executive Director
4,733
17.19
US$81,363 		4,733 17.19 US$81,363
2023-06-09 2023-06-09 PrS Proposed sale
SUZANNE BLAUG

Director

Non-Executive Director
8,520
17.20
US$146,553 		8,520 17.20 US$146,553
2023-06-09 2023-06-09 PrS Proposed sale
JEFFREY L EDWARDS

Director

Non-Executive Director
7,889
17.19
US$135,607 		7,889 17.19 US$135,607
2023-06-09 2023-06-09 PrS Proposed sale
BENJAMIN CRAVATT

Director

Non-Executive Director
3,944
17.17
US$67,723 		3,944 17.17 US$67,723
2023-06-09 2023-06-09 PlS Planned sale
Brennan Aoife
Non-Executive Director
2,739 -8.9%
17.52
US$47,987 		2,739 -8.9% 17.52 US$47,987
2023-06-09 2023-06-09 PlS Planned sale
Brennan Aoife
Non-Executive Director
1,994 -6.1%
16.74
US$33,380 		1,994 -6.1% 16.74 US$33,380
2023-06-09 2023-06-09 PlS Planned sale
EDWARDS JEFFREY L
Non-Executive Director
4,624 -12.0%
17.51
US$80,966 		4,624 -12.0% 17.51 US$80,966
2023-06-09 2023-06-09 PlS Planned sale
EDWARDS JEFFREY L
Non-Executive Director
3,265 -7.8%
16.74
US$54,656 		3,265 -7.8% 16.74 US$54,656
2023-06-09 2023-06-09 PlS Planned sale
Blaug Suzanne
Non-Executive Director
5,169 -14.9%
17.51
US$90,509 		5,169 -14.9% 17.51 US$90,509
2023-06-09 2023-06-09 PlS Planned sale
Blaug Suzanne
Non-Executive Director
3,351 -8.8%
16.73
US$56,062 		3,351 -8.8% 16.73 US$56,062
2023-06-09 2023-06-09 PlS Planned sale
Cravatt Benjamin
Non-Executive Director
2,178 -7.0%
17.51
US$38,137 		2,178 -7.0% 17.51 US$38,137
2023-06-09 2023-06-09 PlS Planned sale
Cravatt Benjamin
Non-Executive Director
1,766 -5.4%
16.75
US$29,580 		1,766 -5.4% 16.75 US$29,580
2023-06-09 2023-06-08 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
4,994 -12.5%
17.69
US$88,344 		4,994 -12.5% 17.69 US$88,344
2023-06-09 2023-06-08 PlS Planned sale
2.9
Henderson Jeffrey William
Non-Executive Director
2,006 -4.8%
16.87
US$33,841 		2,006 -4.8% 16.87 US$33,841
2023-06-09 2023-06-08 PlS Planned sale
Ho Maykin
Non-Executive Director
6,225 -16.5%
17.68
US$110,058 		6,225 -16.5% 17.68 US$110,058
2023-06-09 2023-06-08 PlS Planned sale
Ho Maykin
Non-Executive Director
2,295 -5.7%
16.79
US$38,533 		2,295 -5.7% 16.79 US$38,533
2023-06-08 2023-06-08 PrS Proposed sale
2.9
Jeffrey Henderson

Director

Non-Executive Director
7,000
17.78
US$124,460 		7,000 17.78 US$124,460
2023-06-08 2023-06-08 PrS Proposed sale
May-Kin Ho

Director

Non-Executive Director
8,520
17.78
US$151,486 		8,520 17.78 US$151,486
2023-06-08 2023-06-08 PrS Proposed sale
3.9
Graham Juan

Officer

Officer
1,050
16.95
US$17,797 		1,050 16.95 US$17,797
2023-06-09 2023-06-07 S Sale
4.0
Eisner Mark

EVP, Chief Medical Officer

Officer
2,042 -1.2%
17.04
US$34,792 		2,042 -1.2% 17.04 US$34,792
2023-06-09 2023-06-07 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
1,286 -1.1%
17.04
US$21,910 		1,286 -1.1% 17.04 US$21,910
2023-06-09 2023-06-07 PlS Planned sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
472 -0.4%
17.04
US$8,041 		472 -0.4% 17.04 US$8,041
2023-06-09 2023-06-07 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
6,106 -1.6%
17.04
US$104,033 		6,106 -1.6% 17.04 US$104,033
2023-06-09 2023-06-07 PlS Planned sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
2,791 -0.7%
17.04
US$47,550 		2,791 -0.7% 17.04 US$47,550
2023-06-09 2023-06-07 PlS Planned sale
3.1
Schoeneck James A
Non-Executive Director
7,100 -8.8%
18.03
US$127,987 		7,100 -8.8% 18.03 US$127,987
2023-06-09 2023-06-07 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
735 -1.0%
17.04
US$12,523 		735 -1.0% 17.04 US$12,523
2023-06-09 2023-06-07 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
1,050 -1.4%
16.95
US$17,797 		1,050 -1.4% 16.95 US$17,797
2023-06-09 2023-06-07 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
1,532 -0.6%
17.04
US$26,102 		1,532 -0.6% 17.04 US$26,102
2023-06-09 2023-06-07 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
739 -0.3%
17.04
US$12,590 		739 -0.3% 17.04 US$12,590
2023-06-09 2023-06-07 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
1,362 -0.5%
17.04
US$23,202 		1,362 -0.5% 17.04 US$23,202
2023-06-07 2023-06-07 PrS Proposed sale
3.1
Schoeneck James A

Director

Non-Executive Director
7,100
18.03
US$127,987 		7,100 18.03 US$127,987
2023-06-07 2023-06-07 PrS Proposed sale
3.9
Graham Juan

Officer

Officer
1,406
17.04
US$23,956 		1,406 17.04 US$23,956
2023-06-07 2023-06-07 PrS Proposed sale
3.6
Wettig Thane

Officer

Officer
1,758
17.04
US$29,951 		1,758 17.04 US$29,951
2023-06-07 2023-06-07 PrS Proposed sale
4.0
Eisner Mark

Officer

Officer
2,042
17.04
US$34,792 		2,042 17.04 US$34,792
2023-06-07 2023-06-07 PrS Proposed sale
3.9
Chung Christine

Officer

Officer
3,633
17.02
US$61,839 		3,633 17.02 US$61,839
2023-06-05 2023-06-02 S Sale
4.0
Eisner Mark

EVP, Chief Medical Officer

Officer
1,090 -0.7%
18.83
US$20,525 		1,090 -0.7% 18.83 US$20,525
2023-06-02 2023-06-02 PrS Proposed sale
4.0
Eisner Mark

Officer

Officer
1,090
18.83
US$20,525 		1,090 18.83 US$20,525
2023-04-11 2023-04-10 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
1,869 -0.5%
19.52
US$36,483 		1,869 -0.5% 19.52 US$36,483
2023-04-06 2023-04-04 S Sale
4.0
Eisner Mark

Chief Medical Officer

Officer
9,182 -5.2%
18.78
US$172,473 		9,182 -5.2% 18.78 US$172,473
2023-04-06 2023-04-04 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
6,590 -2.5%
18.78
US$123,785 		6,590 -2.5% 18.78 US$123,785
2023-03-24 2023-03-23 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
905 -0.8%
18.71
US$16,933 		905 -0.8% 18.71 US$16,933
2023-03-10 2023-03-10 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
2,344 -3.1%
20.20
US$47,342 		2,344 -3.1% 20.20 US$47,342
2023-03-10 2023-03-10 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
1,456 -1.9%
20.20
US$29,407 		1,456 -1.9% 20.20 US$29,407
2023-03-10 2023-03-10 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
1,112 -1.4%
20.20
US$22,459 		1,112 -1.4% 20.20 US$22,459
2023-03-10 2023-03-10 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
19,486 -4.8%
20.20
US$393,565 		19,486 -4.8% 20.20 US$393,565
2023-03-10 2023-03-10 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
12,103 -2.9%
20.20
US$244,448 		12,103 -2.9% 20.20 US$244,448
2023-03-10 2023-03-10 S Sale
4.0
Eisner Mark

Chief Medical Officer

Officer
6,255 -3.4%
20.20
US$126,334 		6,255 -3.4% 20.20 US$126,334
2023-03-10 2023-03-10 S Sale
4.0
Eisner Mark

Chief Medical Officer

Officer
3,885 -2.1%
20.20
US$78,467 		3,885 -2.1% 20.20 US$78,467
2023-03-10 2023-03-10 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
4,731 -4.1%
20.20
US$95,553 		4,731 -4.1% 20.20 US$95,553
2023-03-10 2023-03-10 S Sale
3.6
Wettig Thane

Chief Commercial Officer

Officer
2,938 -2.5%
20.20
US$59,340 		2,938 -2.5% 20.20 US$59,340
2023-03-10 2023-03-10 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
2,914 -1.1%
20.20
US$58,855 		2,914 -1.1% 20.20 US$58,855
2023-03-10 2023-03-10 S Sale
3.9
Chung Christine

SVP, China Operations

Officer
4,692 -1.8%
20.20
US$94,766 		4,692 -1.8% 20.20 US$94,766
2023-03-10 2023-03-08 S Sale
3.9
Graham Juan

Chief Financial Officer

Officer
2,749 -3.8%
21.16
US$58,158 		2,749 -3.8% 21.16 US$58,158
2023-03-10 2023-03-08 S Sale
2.8
Conterno Enrique A

Chief Executive Officer

Executive Director
24,672 -6.5%
21.16
US$521,958 		24,672 -6.5% 21.16 US$521,958
Explore more

More insider trading research around FibroGen Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America